Summit Therapeutics PLC Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Summit Therapeutics PLC, a foreign private issuer, for the month of October 2019. The report was submitted on October 11, 2019, and is incorporated by reference into the Company's Registration Statement on Form F-3 (File No. 333-232074).
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change disclosed is the resignation of Ms. Valerie Andrews from the Board of Directors, effective immediately on October 11, 2019. The Company stated that her resignation was not related to any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks, contingencies, or unusual items were disclosed in this report other than the board composition change.
Key Facts for Investor Verification
- Ms. Valerie Andrews resigned from the Board of Directors effective October 11, 2019.
- The resignation was explicitly stated as unrelated to any disagreement with the Company.
- A press release detailing this event is attached as Exhibit 99.1.
- The report was signed by Glyn Edwards, Chief Executive Officer.